Proactiveinvestors recommends
Additional Information
Market: LSE
Sector: Pharmaceuticals & Biotechnology
EPIC: ATD
Latest Price: 1.75p  (-6.91% Descending)
52-week High: 13.50p
52-week Low: 1.25p
Market Cap: 2.07M
1 year chart
digital-look imported chart image
1 day chart
digital-look imported chart image
Watchlist/Portfolio

Add to watchlist:

Only registered members can add into watchlist !

Register here !
Asterand
www.asterand.com

Asterand plc is the leading global supplier of high quality, well characterized human tissue and human tissue-based research services to drug discovery scientists. Our mission is to provide human tissues and services to accelerate the identification and validation of drug targets and enhance the selection of drug candidates with an increased likelihood of clinical success.

Full Asterand profile here
Is ATD a Buy, Sell or Hold?Get your FREE analysis of ATD
Pdf

Asterand added to Daniel Stewart’s Top Picks portfolio

20th Mar 2009, 2:43 pm Asterand added to Daniel Stewart’s Top Picks portfolio

Asterand PLC has been added to Daniel Stewart & Co’s Top Picks portfolio in a reload that saw six stocks added and eight removed, with the new portfolio comprising 11 stocks.


The investment bank and broker with a focus on small and mid-size companies introduced the Top Picks stock selection in October 2008 as a defensive portfolio selected from within its sector specialisation.


Immunodiagnostic (LSE: IDH) and Tristel (LSE: TSTL) have exited the Healthcare group and have been replaced by Asterand (LSE: ATD) and Epistem (LSE: EHP).  Daniel Stewart said it is recommending human tissue and associated research services provider Asterand and preclinical studies specialist Epistem because the current state of the drug development industry is creating new market opportunities for specialist providers such as these two.


In the Financials segment of the Top Picks list, Daniel Stewart replaced Albemarle & Bond (LSE: ABM), Begbies Traynor (LSE: BEG) and Tenon (LSE: TNO) with Prodesse (LSE: PRD); H&T Group (LSE: HAT) and Vantis (LSE: VTS) were retained. The bank believes Prodesse with its exceptional yield and its focus on AAA-rated mortgage-backed securities issued by the US Government Sponsored Enterprises represents a highly attractive opportunity for income hungry investors, in a market where dividends are being routinely cut.


In Leisure, Playtech (LSE: PTEC) has replaced Neteller, now called Neovia (LSE: NEO), and SportingBet (LSE: SBT) was retained.


Both Sportingbet and Playtech trade at a discount to the sector, have net cash positions and benefit from leading positions in their respective markets, European sports book and gaming software respectively, it said.


In Support Services, Melorio (LSE: MLO) has replaced Nationwide Accident Repair Services (LSE: NARS) while Healthcare Locums (LSE: HLO) was retained. Daniel Stewart believes both Melorio and Healthcare Locums are trading way below their true value and offer substantial upside to its respective target prices.


In Telecoms, Media and Technology, System C Healthcare (LSE: SYS) replaced Earthport (LSE: EPO), and RM PLC (LSE: RM) was retained.


All ratings in the Oil & Gas sector are currently suspended.

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.